To assist enquiries a copy of the amended complaint can be viewed by clicking the following link:Quantum Amended Court Claim TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that on May 1, 2025 it filed an amended complaint in the United States District Court for the Southern District of New Y ...

TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), today announced its licensee – Celly Nutrition Corporation ("Celly Nutrition"), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – has secured a landmark partnership with the Asian American Trade Associations Council ("AATAC") to expand the retail availability of unbuzzd™, increase ...

Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region TORONTO, April 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) "Quantum BioPharma" or the "Company"), today announced its licensee – Celly Nutrition Corporation ("Celly Nutrition"), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptom ...

"We are very excited about the potential of this novel PET biomarker to directly visualize and measure demyelination in the central nervous system", said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. "We expect that this biomarker will be an important diagnostic tool in future MS trials investigating therapies that can prevent demyelination and promote remyelination. This is very relevant to our Lucid-MS clinical development program as Lucid-MS has been shown ...

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the "March 7 NR"). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for $2,42 ...

Financial Performance - The company reported its financial results for the fiscal year ended December 31, 2024, with detailed analysis available in the 2024 Annual MD&A[514]. - No significant trends or uncertainties are expected to adversely affect net revenues or profitability for the period from January 1, 2024, to December 31, 2024[517]. - The total cumulative return for Quantum BioPharma Ltd. was C$3.63 as of December 31, 2024, compared to C$100 on December 31, 2020, indicating a significant decline in shareholder value over the period[559]. Executive Leadership - The company’s executive team includes Anthony Durkacz as Co-Executive Chairman and Zeeshan Saeed as CEO, with a focus on strategic leadership[520]. - Donal Carroll resumed the role of CFO on August 30, 2024, after previously serving in various financial leadership roles[527]. - The company has not disclosed any new products or technologies in the current report, but ongoing R&D efforts are highlighted[516]. Compensation and Governance - The company has a compensation philosophy aimed at aligning executive pay with performance, with specific disclosures for NEOs for the year ended December 31, 2024[538]. - The executive compensation program for the year ended December 31, 2024, included base compensation, potential annual incentive awards, Options, RSUs, and PSUs[541]. - For 2024, Zeeshan Saeed, CEO, received a total compensation of $583,685, which included a salary of $218,635 and share-based awards of $365,050[563]. - The Compensation, Nominating and Governance Committee evaluates executive performance against the Company's goals and compares it with other similar-sized reporting issuers[546]. - The Company aims to provide a competitive compensation package to attract and retain qualified executives while linking compensation to corporate performance[543]. - The Company does not have fixed criteria for determining compensation, opting instead for a contextual analysis based on various factors[547]. - The Board believes that the compensation levels for directors and executive officers should not be directly compared to market performance due to external factors affecting stock prices[559]. Board Structure and Responsibilities - The company’s board includes members with extensive experience in healthcare, finance, and strategic management, enhancing its governance[520][529]. - There are no family relationships among the executive officers or directors, ensuring a professional governance structure[536]. - The Board consists of seven members, with four being independent directors[598][599]. - The Board is responsible for overseeing the development of the Company's strategic plan and ensuring management meets corporate objectives[595]. - The Board has adopted a Code of Conduct and Ethics to guide ethical business conduct and compliance with applicable laws[617]. - The Board's mandate includes assessing the effectiveness of its committees and individual directors[607]. - The Compensation, Nominating and Governance Committee is responsible for recommending candidates for Board nomination and ensuring the Board's effectiveness[640][641]. Employee Relations and Workforce - As of December 31, 2024, the company had seven full-time employees, a decrease from 17 in 2022, with research and development staff reduced from 12 to 2[655][656]. - The company maintains good relations with its employees, with no employees represented by collective bargaining agreements[655]. - The company does not have any women on the Board or in executive officer positions, representing 0%[654]. - The company has not adopted a term limit for directors, considering the benefits of renewal in the context of the Board's needs[649]. - The company does not have specific targets for appointing women to the Board or in executive officer positions[653]. Risk Management - The company operates primarily in Canada, the United States, and Australia, exposing it to foreign currency risk without using financial derivative instruments to manage this risk[797]. - The company holds certain cryptocurrency assets, which exposes it to significant volatility and regulatory risks in the cryptocurrency markets[799]. Audit and Compliance - The Audit Committee meets quarterly to review and approve the unaudited interim and annual audited financial statements, ensuring management fulfills its financial reporting responsibilities[627][628]. - The Audit Committee pre-approved all audit services provided by independent auditors for the fiscal year ended December 31, 2024[637]. - The company established a 401(k) plan on January 31, 2021, which was terminated on December 31, 2021, and currently has no pension plans[579]. - The annual cost for directors' and officers' liability insurance was C$108,000 for the year ended December 31, 2024[588]. - Each director is entitled to an annual retainer of C$50,000, which can be paid in cash, share-based compensation, or a combination of both[591].

Core Insights - Quantum BioPharma Ltd. reported strong financial and operational results for Q4 and the full year 2024, indicating a solid balance sheet and sufficient working capital to sustain operations through January 2027 [2][12]. Financial Performance - Cash and cash equivalents increased to $12.1 million USD as of December 31, 2024, up from $11.1 million USD in 2023, reflecting a positive cash flow situation [3]. - Operating expenses were reduced to $16.1 million USD in 2024, a decrease of over 32% from $23.8 million USD in 2023 [3]. - Net cash used in operations improved by 36%, totaling $6.9 million USD in 2024 compared to $10.8 million USD in 2023 [4]. - The net loss for 2024 was $14.9 million USD, an 18% improvement from the $18.2 million USD loss in 2023 [6]. Research and Development - External research and development fees rose to $6.1 million USD in 2024, up from $3.9 million USD in 2023, due to advancements in key clinical assets [5]. - The company completed a Phase 1 clinical trial for its multiple sclerosis drug, Lucid-21-302, which was deemed safe and well-tolerated [14]. Product Development and Market Strategy - The company has initiated the development of rekvry, an alcohol misuse treatment aimed at emergency and hospital settings, addressing a significant unmet need [8]. - The dietary supplement unbuzzd has shown promising results in clinical trials, significantly reducing blood alcohol concentration and improving alertness without side effects [10][13]. - Celly Nutrition Corp., the licensee for unbuzzd, is exploring an IPO to raise up to $10 million USD and expand market reach [10][15]. Corporate Strategy and Future Outlook - Quantum BioPharma is focused on building a multi-channel distribution strategy for unbuzzd and expanding its availability through e-commerce [12][16]. - The company has engaged in strategic investments, including purchasing $3.5 million worth of Bitcoin and other cryptocurrencies to diversify its treasury [15]. - Management anticipates additional milestone announcements as it continues to develop solutions for brain and inflammatory disorders [17].

Core Insights - Quantum BioPharma Ltd. has reported significant advancements in its clinical trials and financial performance for the year ended December 31, 2024, including the completion of the unbuzzd™ clinical trial and progress in the Lucid-21-302 Phase 1 trial for multiple sclerosis [1][12][14] Financial Performance - The company reported cash and cash equivalents of $12.1 million USD as of December 31, 2024, an increase from $11.1 million USD in 2023 [3] - Operating expenses were reduced to $16.1 million USD in 2024, down from $23.8 million USD in 2023, marking an improvement of over 32% [3] - Net cash used in operations decreased to $6.9 million USD in 2024 from $10.8 million USD in 2023, reflecting a 36% improvement [4] - The net loss for the year was $14.9 million USD, an 18% improvement compared to a net loss of $18.2 million USD in 2023 [6] Clinical Developments - The unbuzzd™ clinical trial demonstrated that the product significantly accelerated the reduction of Blood Alcohol Concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, while also alleviating symptoms of intoxication and hangover [9][13] - The company has initiated the development of rekvry™, a treatment for alcohol misuse, aimed at addressing unmet healthcare needs [8] - The Lucid-21-302 drug for multiple sclerosis has completed a Phase 1 trial, showing safety and tolerability, and is preparing for a Phase 2 trial [14][16] Strategic Initiatives - Celly Nutrition Corp., the licensee for unbuzzd™, is exploring an initial public offering (IPO) and has engaged a New York investment bank to raise up to $10 million USD [9][15] - The company has diversified its treasury by purchasing $3.5 million worth of Bitcoin and other cryptocurrencies, reflecting a strategic approach to enhance liquidity [16][17] - Quantum BioPharma is focused on expanding the distribution of unbuzzd™ through partnerships and e-commerce initiatives [18]

TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company. Mr. Terry Lynch Mr. Lynch is widely known and respected for his role ...

New Ultra-Portable unbuzzd™ Single-Use Powder Sticks in Convenient 8-Pack Display Boxes Now Available for US Retailers TORONTO, March 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), today announced its licensee Celly Nutrition Corporation ("Celly Nutrition"), the company behind unbuzzd™ – a beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – released new unbuzzd™ "On-the-Go Pow ...